FORM 4

UNITE

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

or Section 30(h) of the Investment Company Act of 1940

ED STATES SECURITIES AND EXCHANGE COMMISS	SIU	Ν

		OMB	APPI	ROVAL
--	--	-----	------	-------

OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

1. Name and Address of Reporting Person* <u>Kaye Edward M. MD</u>				2. Issuer Name and Ticker or Trading Symbol Stoke Therapeutics, Inc. [STOK]					(Chec	5. Relationship of Reportin (Check all applicable) Director			ting Person(s) to Issuer			
(Last) (First) (Middle) C/O STOKE THERAPEUTICS, INC. 45 WIGGINS AVENUE					3. Date of Earliest Transaction (Month/Day/Year) 12/03/2024							Officer (below)		Other (specify below)		pecify
(Street) BEDFORD MA 01730 (City) (State) (Zip)					4. If Amendment, Date of Original Filed (Month/Day/Year) 12/05/2024					6. Ind Line)	<u>·</u>					
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																
1. Title of Security (Instr. 3) 2. Trans Date (Month/I			Execution Da h/Day/Year) if any		ecution Date, Transaction		4. Securities Disposed Of	(A) or 3, 4 and 5)	4 and 5) Securities Beneficially Owned Following		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership			
							Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)
Common Stock 12/03					3/2024		M		26,250	A	\$0	74,841]	D	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
Derivative Conversion Date Execution Date, or Exercise (Month/Day/Year)		Cc	ansaction ode (Instr.	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4	6. Date Exercisable and Expiration Date (Month/Day/Year) Title and of Securitie Underlying Derivative S (Instr. 3 and			es G Security	8. Price of Derivative Security (Instr. 5) Security Securitic Securitic Owned Followin		e s ally	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)			

Explanation of Responses:

(1)

(1)

1. Each performance stock unit represents a right to receive one share of the Issuer's common stock.

12/03/2024

12/03/2024

2. This award represents a grant of restricted stock units upon the achievement of certain performance criteria as certified by the Issuer's compensation committee on the Transaction Date.

and 5)

(A)

52 500

(D)

26,250

3. Half the award vests on December 3, 2024 and the remainder shall vest on December 3, 2025, subject to the reporting person's continued service to the Issuer on the relevant vesting date.

Remarks:

Performance

Performance

Stock Units

This Form 4 is being amended to correct the number of performance-based restricted stock units awarded and vested on December 3, 2024 on Table II, and to correct the reporting person's total securities held on Table I accordingly.

Date

Exercisable

(3)

(3)

/s/ Jonathan Allan, Attorney-in-

12/10/2024

Reported

(Instr. 4)

Transaction(s)

52 500

26,250

D

D

Fact

Expiration Date

12/03/2025

12/03/2025

** Signature of Reporting Person

Title

Commo

Stock

Amount

or Number

of Shares

52,500

26,250

\$0

\$0

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Code ν

A⁽²⁾

M

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.